Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Geodyssey Research LLC

Neither a doctor nor a teaching hospital

Research payments

$907,825

856 payments

Through program year 2025, Geodyssey Research LLC is reported as receiving $907,825 in research payments, across 856 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $82,669 105
2024 Research $56,463 67
2023 Research $103,070 99
2022 Research $82,893 103
2021 Research $154,868 184
2020 Research $222,772 144
2019 Research $205,090 154

Breakdown

Who paid Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $233,820 263 payments
  2. Roche Products Limited $203,372 331 payments
  3. Adamas Pharmaceuticals, Inc. $140,375 81 payments
  4. Hoffmann-La Roche Limited $127,272 108 payments
  5. EMD Serono, Inc. $74,623 24 payments
  6. Biogen, Inc. $43,852 1 payment
  7. Genentech, Inc. $38,420 18 payments
  8. Amarin Pharma Inc. $15,400 1 payment
  9. ACADIA Pharmaceuticals Inc $14,244 5 payments
  10. Sunovion Pharmaceuticals Inc. $4,912 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. Study of Ocrelizumab in PPMS Patients Assessing Upper Limb Function $238,771 265 payments
  2. Ocrelizumab in PPMS $162,230 247 payments
  3. A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study to Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment $109,343 46 payments
  4. Roll Over Protocol for 3 Ocr Pivotal Studies Opera I Opera II and Oratorio to Extend the Ole $92,107 93 payments
  5. A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. $74,623 24 payments
  6. A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 $43,852 1 payment
  7. Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment $39,875 84 payments
  8. A Phase III Study to Evaluate the Efficacy and Safety of Fenebrutinib in Adults With Progressive Ms $38,233 17 payments
  9. A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment $31,032 35 payments
  10. A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis $29,143 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record